2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

neutralizing monoclonal antibody

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

1

Peptides

35

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99275
    Patritumab
    1 Publications Verification

    Human Anti-ERBB3 Recombinant antibody

    		 EGFR Akt ERK PARP Survivin Cancer
    Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
    Patritumab
  • HY-P9945
    Mepolizumab

    SB 240563

    		 Interleukin Related Cardiovascular Disease Inflammation/Immunology
    Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
    Mepolizumab
  • HY-P9945A
    Mepolizumab (anti-IL5)

    		Interleukin Related Inflammation/Immunology
    Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
    Mepolizumab (anti-IL5)
  • HY-P99604
    Cilgavimab

    AZD-1061; COV2-2130

    		 SARS-CoV Infection
    Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .
    Cilgavimab
  • HY-P99347
    Etesevimab

    CB 6; JS016

    		 SARS-CoV Angiotensin-converting Enzyme (ACE) Infection
    Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody .
    Etesevimab
  • HY-P99305
    Metelimumab

    CAT-192; Anti-TGFB1 Recombinant antibody

    		 TGF-β Receptor Inflammation/Immunology
    Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that can selectively neutralize TGFβ1 .
    Metelimumab
  • HY-P99615
    Felvizumab

    SB 209763; RSHZ19

    		 RSV Infection
    Felvizumab (SB 209763) is a humanized IgG1κ monoclonal antibody directed to distinct neutralizing epitopes on the F glycoprotein of RSV .
    Felvizumab
  • HY-P99703
    Libivirumab

    17.1.41

    		 HBV Infection
    Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .
    Libivirumab
  • HY-P99307
    Namilumab

    AMG-203; Anti-Human CSF2 Recombinant antibody

    		 c-Fms Inflammation/Immunology
    Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis .
    Namilumab
  • HY-P99889
    Romlusevimab

    BRII-198

    		 SARS-CoV Infection
    Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
    Romlusevimab
  • HY-P99900
    Sevirumab

    MSL-109

    		 CMV Infection
    Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL .
    Sevirumab
  • HY-P99811
    Rafivirumab

    CR57

    		 RABV Infection
    Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails .
    Rafivirumab
  • HY-P99792
    Ormutivimab

    NM57; rhRIG

    		 RABV Infection
    Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .
    Ormutivimab
  • HY-P99750
    Navivumab

    CT-P23

    		 Influenza Virus Infection
    Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2 .
    Navivumab
  • HY-P99626
    Frovocimab

    LY 3015014

    		 Ser/Thr Protease Metabolic Disease
    Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .
    Frovocimab
  • HY-P9953
    Certolizumab pegol

    Certolizumab; CDP870

    		 TNF Receptor Inflammation/Immunology
    Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research .
    Certolizumab pegol
  • HY-P99424
    Afasevikumab

    RG 7624; RO 5553110; NI-1401

    		 Interleukin Related Inflammation/Immunology
    Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities .
    Afasevikumab
  • HY-P99020
    Fresolimumab
    1 Publications Verification

    GC1008

    		 TGF-β Receptor Inflammation/Immunology Cancer
    Fresolimumab (GC1008) is a high-affinity fully human monoclonal antibody that neutralizes the active form of human TGFβ1, TGFβ2, and TGFβ3. Fresolimumab can be used for the research of cancer and fibrotic diseases .
    Fresolimumab
  • HY-P99710
    Lomtegovimab

    BI 767551; DZIF-10c

    		 SARS-CoV Infection
    Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .
    Lomtegovimab
  • HY-P99556
    Tixagevimab

    AZD8895

    		 SARS-CoV Infection
    Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .
    Tixagevimab
  • HY-P99368
    Lacnotuzumab

    MCS110; Anti-Human B7-H3

    		 c-Fms Metabolic Disease Cancer
    Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .
    Lacnotuzumab
  • HY-P99486
    Briakinumab

    ABT-874

    		 Interleukin Related Inflammation/Immunology
    Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .
    Briakinumab
  • HY-P9806
    Anti-MERS-D12 mAb

    MERS-D12; MERS antibody-D12

    		 SARS-CoV Infection
    Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding .
    Anti-MERS-D12 mAb
  • HY-P9949
    Reslizumab

    Sch 55700

    		 Interleukin Related Inflammation/Immunology
    Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively .
    Reslizumab
  • HY-108810
    Canakinumab

    Ilaris; ACZ 885

    		 Interleukin Related Inflammation/Immunology
    Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin .
    Canakinumab
  • HY-P99551
    Tosatoxumab

    KBSA301; AR-301

    		 Antibiotic Infection
    Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent .
    Tosatoxumab
  • HY-P9924
    Ixekizumab

    LY2439821

    		 Interleukin Related Inflammation/Immunology
    Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis .
    Ixekizumab
  • HY-P99340
    Sotrovimab
    1 Publications Verification

    VIR 7831

    		 SARS-CoV Infection
    Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
    Sotrovimab
  • HY-P99583
    Suvratoxumab

    MEDI4893

    		 Bacterial Infection Inflammation/Immunology
    Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .
    Suvratoxumab
  • HY-P99111
    Golimumab

    CNTO-148

    		 TNF Receptor Apoptosis Interleukin Related Caspase Inflammation/Immunology Cancer
    Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research .
    Golimumab
  • HY-P99395
    Talacotuzumab

    JNJ 56022473; CSL 362

    		 Interleukin Related Cancer
    Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .
    Talacotuzumab
  • HY-P99620
    Firivumab

    CT-P22; CT120

    		 Influenza Virus Infection
    Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice .
    Firivumab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: